[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV)11/19/2025. The transactions were coded as open-market sales, with blocks of shares sold at prices between $20.16 and $20.25 per share through QVT Financial Investment Cayman Ltd.

Following these sales, the reporting person shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd. The filing notes that the individual is a shareholder of that entity but has no voting or investment control over it and expressly disclaims beneficial ownership of the reported shares beyond any pecuniary interest.

11/21/2025 - 08:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANCHESTER KEITH S

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/19/2025		S		850,000	D	$20.25	18,497,727	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	11/19/2025		S		150,000	D	$20.2	18,347,727	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	11/19/2025		S		125,000	D	$20.16	18,222,727	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	11/19/2025		S		175,000	D	$20.24	18,047,727	I(1)	Held by QVT Financial Investment Cayman Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

	/s/ Keith Manchester	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences (ROIV) report in this Form 4?

The Form 4 reports that a director of Roivant Sciences Ltd. had multiple open-market sales of common shares on 11/19/2025, conducted indirectly through QVT Financial Investment Cayman Ltd. at prices around $20.16–$20.25 per share.

At what prices were Roivant Sciences (ROIV) shares sold in the reported trades?

The reported open-market sales of Roivant common shares on 11/19/2025 occurred at prices of $20.25, $20.20, $20.16, and $20.24 per share.

How many Roivant Sciences (ROIV) shares does the reporting person show as beneficially owned after the transactions?

After the reported transactions on 11/19/2025, the filing shows 18,047,727 Roivant common shares beneficially owned on an indirect basis through QVT Financial Investment Cayman Ltd.

What is the reporting person’s relationship to Roivant Sciences (ROIV)?

The individual filing the Form 4 is identified as a director of Roivant Sciences Ltd. and is filing as one reporting person.

How is QVT Financial Investment Cayman Ltd. involved in the Roivant (ROIV) Form 4?

The Roivant shares involved in the transactions are held by QVT Financial Investment Cayman Ltd. The reporting person is a shareholder of that entity but states they have no voting or investment control over it.

Does the reporting person claim full beneficial ownership of the Roivant (ROIV) shares?

No. The filing states that the reporting person disclaims beneficial ownership of the securities held by QVT Financial Investment Cayman Ltd., except to the extent of any pecuniary interest.